For the remnant three patients, our MTB recommended compassionate treatment for histology not yet approved by AIFA (Ivosidenib for a patient with cholangiocarcinoma presented IDH1 mutation, Selpercatinib for a patient with adenocarcinoma of the esophagus presented RET mutation and then Olaparib/Niraparib for HRD). Here, RET is linked to cholangiocarcinoma.